Clopidogrel bisulfate: in ST-segment elevation myocardial infarction

Area of Science:

• Cardiology
• Pharmacology
• Clinical Trials

Background:

• Clopidogrel is an antiplatelet medication used to prevent atherothrombotic events.
• ST-segment elevation myocardial infarction (STEMI) is a critical condition requiring prompt treatment to reduce mortality and morbidity.

Purpose of the Study:

• To evaluate the efficacy and safety of clopidogrel in combination with aspirin for STEMI patients.
• To assess the impact of clopidogrel on reducing major adverse cardiovascular events and mortality in STEMI.

Main Methods:

• Analysis of data from two large clinical trials: COMMIT/CCS-2 (45,852 patients) and CLARITY-TIMI 28 (3,491 patients).
• Comparison of clopidogrel plus aspirin versus aspirin alone or aspirin plus placebo in STEMI patients.

Main Results:

• Clopidogrel plus aspirin significantly reduced the composite endpoint of reinfarction, stroke, or death from any cause in STEMI patients.
• Treatment with clopidogrel 75 mg/day plus aspirin for approximately two weeks prevented nine major adverse events per 1000 patients treated.
• No significant difference in major bleeding rates was observed between clopidogrel plus aspirin and control groups.

Conclusions:

• Clopidogrel in combination with aspirin is effective in reducing atherothrombotic events in STEMI patients.
• The combination therapy is generally well-tolerated, with a favorable safety profile regarding major bleeding.
• Longer-term clopidogrel monotherapy has also shown good tolerability in other patient populations.